Neurocrine Biosciences Inc (NBIX): Total Liabilities
$1.38B
As of 2025-12-31
$1.67B
As of 2026-06-30
+27.8%
3-year compound annual growth
+17.8%
5-year compound annual growth
+39.2%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.38B | +22.1% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $1.13B | +10.8% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $1.02B | +54.2% | 2025-02-10, Balance as of period end |
| 2022-12-31 | $660.90M | -5.4% | 2024-02-09, Balance as of period end |
| 2021-12-31 | $698.50M | +14.8% | 2023-02-09, Balance as of period end |
| 2020-12-31 | $608.50M | -9.1% | 2022-02-11, Balance as of period end |
| 2019-12-31 | $669.10M | +30.6% | 2021-02-05, Balance as of period end |
| 2018-12-31 | $512.39M | +15.0% | 2020-02-07, Balance as of period end |
| 2017-12-31 | $445.45M | +787.2% | 2019-02-08, Balance as of period end |
| 2016-12-31 | $50.21M | -0.2% | 2018-02-13, Balance as of period end |
| 2015-12-31 | $50.33M | +46.6% | 2017-02-14, Balance as of period end |
| 2014-12-31 | $34.33M | +0.2% | 2016-02-11, Balance as of period end |
| 2013-12-31 | $34.27M | -17.6% | 2015-02-09, Balance as of period end |
| 2012-12-31 | $41.61M | -46.9% | 2014-02-11, Balance as of period end |
| 2011-12-31 | $78.29M | -37.4% | 2013-02-08, Balance as of period end |
| 2010-12-31 | $125.08M | n/a | 2012-02-09, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.38B | +22.1% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $683.10M | -2.9% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $3.69B | +13.8% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.48B | +45.7% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.30B | -40.3% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $633.31M | -34.5% |
| Biogen Inc. (BIIB) | 2025-12-31 | $11.18B | -1.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.92M | +5.2% |
Compare NBIX, EXEL, MRNA, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗